CoChat

Exploring the Significance of the Exon 4-Skipping Isoform of the ZNF217 Oncogene in Breast Cancer

Bellanger, Aurélie, Le, Diep T., Vendrell, Julie, Wierinckx, Anne, Pongor, Lőrinc S., Solassol, Jérôme, Lachuer, Joël, Clezardin, Philippe, Győrffy, Balázs, Cohen, Pascale A. · 2021 · Frontiers in Oncology
Cited by 7

The DOI matches its Crossref record.

Abstract

Oncogene alternative splicing events can create distinct functional transcripts that offer new candidate prognostic biomarkers for breast cancer. ZNF217 is a well-established oncogene but its exon 4-skipping isoform (ZNF217-ΔE4) has never been investigated in terms of clinical or biological relevance. Using in silico RNA-seq and RT-qPCR analyses, we demonstrated for the first time the existence of ZNF217-ΔE4 transcripts in primary breast tumors, and a positive correlation between ZNF217-ΔE4 mRNA levels and those of the wild-type oncogene (ZNF217-WT). A pilot retrospective analysis revealed that, in the Luminal subclass, the combination of the two ZNF217 variants (the ZNF217-ΔE4-WT gene-expression signature) provided more information than the mRNA expression levels of each isoform alone. Ectopic overexpression of ZNF217-ΔE4 in breast cancer cells promoted an aggressive phenotype and an increase in ZNF217-WT expression levels that was inversely correlated with DNA methylation of the ZNF217 gene. This study provides new insights into the possible role of the ZNF217-ΔE4 splice variant in breast cancer and suggests a close interplay between the ZNF217-WT and ZNF217-ΔE4 isoforms. Our data suggest that a dual signature combining the expression levels of these two isoforms may serve as a novel prognostic biomarker allowing better stratification of breast cancers with good prognosis and aiding clinicians in therapeutic decisions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fonc.2021.647269

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 29

  1. Collins, 1998, Positional Cloning of ZNF217 and NABC1: Genes Amplified at 20q13.2 and Overexpressed in Breast Carcinoma, Proc Natl Acad Sci USA, 95, 10.1073/pnas.95.15.8703 · DOI · Paper page
  2. Cohen, 2015, The Dark Side of ZNF217, A Key Regulator of Tumorigenesis With Powerful Biomarker Value, Oncotarget, 6, 10.18632/oncotarget.5893 · DOI
  3. Thollet, 2010, ZNF217 Confers Resistance to the Pro-Apoptotic Signals of Paclitaxel and Aberrant Expression of Aurora-a in Breast Cancer Cells, Mol Cancer, 9, 10.1186/1476-4598-9-291 · DOI
  4. Vendrell, 2012, ZNF217 Is a Marker of Poor Prognosis in Breast Cancer That Drives Epithelial-Mesenchymal Transition and Invasion, Cancer Res, 72, 10.1158/0008-5472.CAN-11-3095 · DOI
  5. Bellanger, 2017, The Critical Role of the ZNF217 Oncogene in Promoting Breast Cancer Metastasis to the Bone, J Pathol, 242, 73, 10.1002/path.4882 · DOI
  6. Nguyen, 2014, A Functional Interplay Between ZNF217 and Estrogen Receptor Alpha Exists in Luminal Breast Cancers, Mol Oncol, 8, 10.1016/j.molonc.2014.05.013 · DOI · Paper page
  7. Ladomery, 2013, Aberrant Alternative Splicing is Another Hallmark of Cancer, Int J Cell Biol, 2013, 10.1155/2013/463786 · DOI · Paper page
  8. Martinez-Montiel, 2017, Alternative Splicing in Breast Cancer and the Potential Development of Therapeutic Tools, Genes (Basel), 8, 10.3390/genes8100217 · DOI
  9. Koboldt, 2012, Comprehensive Molecular Portraits of Human Breast Tumours, Nature, 490, 61, 10.1038/nature11412 · DOI · Paper page
  10. Stephenson, 1971, Induction of Colonies of Hemoglobin-Synthesizing Cells by Erythropoietin In Vitro, Proc Natl Acad Sci USA, 68, 10.1073/pnas.68.7.1542 · DOI · Paper page
  11. Gnant, 2011, St. Gallen 2011: Summary of the Consensus Discussion, Breast Care (Basel), 6, 10.1159/000328054 · DOI · Paper page
  12. Goldhirsch, 2011, Strategies for Subtypes–Dealing With the Diversity of Breast Cancer: Highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011, Ann Oncol, 22, 10.1093/annonc/mdr304 · DOI · Paper page
  13. Goldhirsch, 2013, Personalizing the Treatment of Women With Early Breast Cancer: Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013, Ann Oncol, 24, 10.1093/annonc/mdt303 · DOI · Paper page
  14. Etcheverry, 2010, DNA Methylation in Glioblastoma: Impact on Gene Expression and Clinical Outcome, BMC Genomics, 11, 10.1186/1471-2164-11-701 · DOI · Paper page
  15. Leu, 2004, Loss of Estrogen Receptor Signaling Triggers Epigenetic Silencing of Downstream Targets in Breast Cancer, Cancer Res, 64, 10.1158/0008-5472.CAN-04-2045 · DOI · Paper page
  16. Ness, 2021, Integrated Differential DNA Methylation and Gene Expression of Formalin-Fixed Paraffin-Embedded Uveal Melanoma Specimens Identifies Genes Associated With Early Metastasis and Poor Prognosis, Exp Eye Res, 203, 10.1016/j.exer.2020.108426 · DOI
  17. Renner, 2013, Integrative DNA Methylation and Gene Expression Analysis in High-Grade Soft Tissue Sarcomas, Genome Biol, 14, 10.1186/gb-2013-14-12-r137 · DOI
  18. Trincado, 2016, The Prognostic Potential of Alternative Transcript Isoforms Across Human Tumors, Genome Med, 8, 85, 10.1186/s13073-016-0339-3 · DOI
  19. Yang, 2019, Aberrant Alternative Splicing in Breast Cancer, J Mol Cell Biol, 11, 10.1093/jmcb/mjz033 · DOI
  20. Venables, 2008, Identification of Alternative Splicing Markers for Breast Cancer, Cancer Res, 68, 10.1158/0008-5472.CAN-08-1769 · DOI · Paper page
  21. Yang, 2020, Novel Alternative Splicing Variants of Klf4 Display Different Capacities for Self-Renewal and Pluripotency in Mouse Embryonic Stem Cells, Biochem Biophys Res Commun, 532, 10.1016/j.bbrc.2020.08.054 · DOI
  22. Syafruddin, 2020, Two Sides of the Same Coin: The Roles of KLF6 in Physiology and Pathophysiology, Biomolecules, 10, 1378, 10.3390/biom10101378 · DOI
  23. Wang, 2018, Context-Dependent Functions of KLF4 in Cancers: Could Alternative Splicing Isoforms Be the Key, Cancer Lett, 438, 10.1016/j.canlet.2018.09.005 · DOI
  24. Zhang, 2019, The KLF6 Splice Variant KLF6-SV1 Promotes Proliferation and Invasion of Non-Small Cell Lung Cancer by Up-Regultating PI3K-AKT Signaling Pathway, J Cancer, 10, 10.7150/jca.34212 · DOI
  25. Widschwendter, 2008, Epigenotyping in Peripheral Blood Cell DNA and Breast Cancer Risk: A Proof of Principle Study, PloS One, 3, e2656, 10.1371/journal.pone.0002656 · DOI
  26. Cowger, 2007, Biochemical Characterization of the Zinc-Finger Protein 217 Transcriptional Repressor Complex: Identification of a ZNF217 Consensus Recognition Sequence, Oncogene, 26, 10.1038/sj.onc.1210126 · DOI
  27. Quinlan, 2006, Specific Recognition of ZNF217 and Other Zinc Finger Proteins At a Surface Groove of C-Terminal Binding Proteins, Mol Cell Biol, 26, 10.1128/MCB.00680-06 · DOI · Paper page
  28. Adhikari, 2016, M5A: Signaling for mRNA Splicing, RNA Biol, 13, 10.1080/15476286.2016.1201628 · DOI
  29. Aguilo, 2015, Coordination of m6A mRNA Methylation and Gene Transcription by ZFP217 Regulates Pluripotency and Reprogramming, Cell Stem Cell, 17, 689, 10.1016/j.stem.2015.09.005 · DOI · Paper page

Cited by

See all 7

Metadata

Authors
Bellanger, A., Le, D. T., Vendrell, J., Wierinckx, A., Pongor, L. S., Solassol, J., Lachuer, J., Clezardin, P., Győrffy, B., & Cohen, P. A.
Venue
Frontiers in Oncology
Published
2021-07-02
Volume
11
ISSN
2234-943X
Cited by
7
References
0

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Exploring the Significance of the Exon 4-Skipping Isoform of the ZNF217 Oncogene in Breast Cancer. https://app.cochat.ai/papers/10.3389/fonc.2021.647269
The paper
Bellanger, A., Le, D. T., Vendrell, J., Wierinckx, A., Pongor, L. S., Solassol, J., Lachuer, J., Clezardin, P., Győrffy, B., & Cohen, P. A. (2021). Exploring the Significance of the Exon 4-Skipping Isoform of the ZNF217 Oncogene in Breast Cancer. Frontiers in Oncology. https://doi.org/10.3389/fonc.2021.647269

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.